Moderna is trading 5.67% up at $146.77 after renewed investor attention to positive Phase 3 results for its personalized melanoma vaccine.
- Moderna and Merck reported the vaccine reduced recurrence and spread in high-risk patients; recent profit-taking had cooled the rally.
- Moderna rebounded from its August 24, 2026 close of $138.89.
- The Nasdaq is up 0.67%, offering broader risk-on support; no separate August 25 company announcement was identified.